Priority Lists
Protocol Posting of
Activations
Closures
Permanently closed effective 7/18/02
A Randomized Phase III Trial of Combinations of Oxaliplatin (OXAL), 5-Fluorouracil (5-FU) and Irinotecan (CPT-11) as Initial Treatment of Patients With Advanced Adenocarcinoma of the Colon and Rectum
| Study Coordinator(s) | Stephen K. Williamson, M.D. |
| Participants | Members, Surgeons, NCORP |
| Closure Date | 2002-07-18 |
Amendments, Revisions, Memoranda
Memorandum
A Phase III Prospective Randomized Study of Adjuvant Chemotherapy with Vinorelbine and Cisplatin in Completely Resected Non-Small Cell Lung Cancer with Companion Tumour Marker Evaluation
| Study Coordinator(s) | Robert B. Livingston, M.D. |
| Participants | Members, Medical Oncologists, Pathologists, Surgeons, NCORP |
Revision #8
Randomized Phase III Trial of Carboplatin and Paclitaxel plus Tirapazamine versus Carboplatin and Paclitaxel in Patients with Advanced Non-Small Cell Lung Cancer Cisplatin, Paclitaxel, Tirapazamine vs. Cisplatin, Paclitaxel Specimen submission per S9925
| Study Coordinator(s) | Stephen K. Williamson, M.D., Primo N. Lara, Jr., M.D. |
| Participants | Members, NCORP, Medical Oncologists, Pathologists, EPP, CTSU |
Amendment #2
A Phase II Trial of Epothilone B Analogue BMS-247550 (NSC #710428) Every 21 Days in Patients With Advanced Pancreas Cancer
| Study Coordinator(s) | Robert P. Whitehead, M.D. |
| Participants | Members, NCORP |
Memorandum
Bevacizumab (rhuMAb) (NSC 704865) Therapy For Patients With Relapsed Aggressive Non-Hodgkin's Lymphoma
| Study Coordinator(s) | Alison T. Stopeck, M.D., Thomas P. Miller, M.D., Thomas M. Grogan, M.D., William T. Bellamy, R. Ph. |
| Participants | Members, NCORP, Medical Oncologists, Pathologists |
REACTIVATION Effective July 1, 2002
S0112, A Phase II Study Of Daunomycin And Ara-C, Both Given By Continuous IV Infusion For Previously Untreated Non-M3 Acute Myeloid Leukemia (AML) In Patients Of Age 56 Or Older.
| Study Coordinator(s) | Thomas R. Chauncey, M.D.,Ph.D., Alan F. List, M.D., David R. Head, M.D., Cheryl L. Willman, M.D., Marilyn L. Slovak, Ph.D. |
| Participants | Members, NCORP, Medical Oncologists, Pathologists |
Amendment #2
A Phase II Trial of STI571 for the Treatment of Platinum and Taxane Refractory Stage III and IV Epithelial Ovarian Cancer and Primary Peritoneal Cancer
| Study Coordinator(s) | Andy Jang, M.D., Sharon Wilczynski, M.D.,Ph.D. |
| Participants | Members, NCORP, Medical Oncologists, Surgeons, Pathologists |
Revision #9
A Randomized Comparison of Medroxyprogesterone Acetate (MPA) and Observation For Prevention of Endometrial Pathology in Postmenopausal Breast Cancer Patients Treated with Tamoxifen
| Study Coordinator(s) | Ronald K. Potkul, M.D., Caryl G. Salomon, M.D., Sharon Wilczynski, M.D.,Ph.D. |
| Participants | Members, Medical Oncologists, Radiation Oncologists, Surgeons, Pathologists, CALGB, NCORP |
Revision #7
Phase II Evaluation of Intravenous Paclitaxel, Intraperitoneal Cisplatin, Intravenous Liposomal Doxorubicin and Intraperitoneal Paclitaxel in Women with Optimally-Debulked Stage III Epithelial Ovarian, Primary Peritoneal or Fallopian Tube Cancer
| Study Coordinator(s) | Harriet O. Smith, M.D., Amy D. Tiersten, M.D., Sharon Wilczynski, M.D.,Ph.D. |
| Participants | Members, Surgeons, Pathologists, NCORP |
Revision #11
Docetaxel and Estramustine Versus Mitoxantrone and Prednisone for Advanced, Hormone Refractory Prostate Cancer, Phase III.
| Study Coordinator(s) | Daniel P. Petrylak, M.D., Jeffrey A. Jones, M.D., Maha H.A. Hussain, M.D., Donna L. Berry, R.N.,Ph.D. |
| Participants | UCOP, Medical Oncologists, Surgeons, CALGB, NCCTG, EPP, NCORP, Members, CTSU |
Revision #11
Adjuvant Androgen Deprivation Versus Mitoxantrone Plus Prednisone Plus Androgen Deprivation in Selected High Risk Prostate Cancer Patients Following Radical Prostatectomy, Phase III.
| Study Coordinator(s) | L. Michael Glode, M.D., Maha H.A. Hussain, M.D., Gregory P. Swanson, M.D., David P. Wood Jr., M.D., Wael A. Sakr, M.D. |
| Participants | Members, NCORP, Affiliates, UCOP, Medical Oncologists, Surgeons, Radiation Oncologists, Pathologists, EPP, CALGB, CTSU Institutions in the United States |
Revision #7
Randomized Trial of Post-Mastectomy Radiotherapy in Stage II Breast Cancer in Women With One to Three Positive Axillary Nodes, Phase III
| Study Coordinator(s) | Lori J. Pierce, M.D. |
| Participants | Medical Oncologists, Radiation Oncologists, Surgeons, NCCTG, RTOG, ACOSOG, ECOG, CALGB, NCORP, Members, NCIC-CTG, NSABP |
Revision #12
Randomized Multi-Institutional Phase III Trial of BEP and High Dose Chemotherapy Versus BEP Alone in Previously Untreated Patients With Poor and Intermediate Risk Germ Cell Tumors
| Study Coordinator(s) | Kim A. Margolin, M.D., Patrick J. Stiff, M.D., Michael F. Sarosdy, M.D. |
| Participants | Limited Institutions: SWOG Approved Autologous BMT Facilities |
Other New Items
- IP - Pts Must Be Informed
- AC - Consent Must Be Amended
- CBR - No Registration Allowed until IRB Review
- RC - Formal Re-consent Required
- FBR - Full Board Review Required
- ER - Expedited Review Acceptable
- NR - No IRB Review Required